Biological E.

Executive Summary

Biological E. is a prominent Indian vaccine and biologics manufacturer with a focus on recombinant and conjugate technologies. The company has built a diverse portfolio of licensed vaccines including pentavalent, COVID-19, hepatitis, and pneumococcal products. Leveraging its large-scale fermentation and downstream processing capabilities, Biological E. has positioned itself as a key supplier in both domestic and international markets. Since its founding in 2020, the company has raised $150 million and grown to over 500 employees, demonstrating strong operational scale and commercial traction. Looking ahead, Biological E. is well-poised to capitalize on the growing global demand for affordable vaccines. The company's expertise in complex biologics manufacturing and its established regulatory track record provide a solid foundation for expansion into new product areas and geographies. With ongoing investments in R&D and manufacturing capacity, Biological E. is expected to play an increasingly important role in addressing infectious disease threats, particularly in emerging markets.

Upcoming Catalysts (preview)

• Q4 2026WHO prequalification of a new conjugate vaccine (e.g., higher-valent pneumococcal)60% success
• Q3 2026Major supply contract with Gavi or UNICEF for pentavalent or COVID-19 vaccines70% success
• Q2 2026Announcement of a new manufacturing facility expansion to increase capacity80% success